Video

Recent Updates from the PhALLCON Study

Author(s):

Amanda Przespolewski, DO,Ibrahim Aldoss, MD, City of Hope Comprehensive Cancer Center

Medical experts highlight recent findings from the PhALLCON study.

Current Time 0:00
Duration 5:35
Loaded: 0%
Stream Type LIVE
Remaining Time 5:35
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
Related Videos
Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
Ongoing Research to Watch in Ovarian Cancer
Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Additional Potential Roles for Mirvatuximab Soravtansine and Other ADCs in Ovarian Cancer
Floortje J. Backes, MD, discusses data for mirvatuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer
PICCOLO Data for Mirvatuximab Soravtansine in FRα+, Platinum-Sensitive Ovarian Cancer
Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.
Testing for FRα in Ovarian Cancer
Floortje J Backes, MD, discusses how mirvatuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
How Mirvatuximab Soravtansine Has Impacted Clinical Management of Ovarian Cancer
Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.
Current Treatment Considerations for Platinum-Resistant Ovarian Cancer
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024..
Other Key Follicular Lymphoma Data From ASH 2024
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Data for Mosunetuzumab in Newly Diagnosed Follicular Lymphoma
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
2-Year Follow-Up Data for Liso-Cel in R/R Follicular Lymphoma
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.
CD19 Expression Loss and Tafasitamab in R/R DLBCL
Related Content